Accumulating evidence demonstrated that miRNAs affect tumor angiogenesis and prognosis in patients with NSCLC by downregulating pro‐angiogenic factors by repressing various signaling pathways, such as the VEGF or c‐Met/phosphoinosmde‐3‐kinase (PI3k)/Akt/mammalian target of rapamycin (mTOR) pathway 10, 27, 28. The gene discussed is MTOR; the disease is non-small cell lung carcinoma.